Drugs / 1790GAHB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03089879 | Mar → Aug 2017 | shigellosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02676895 | Aug 2016 → Mar 2017 | shigellosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1790GAHB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03089879 ↗ |
| Modality | Vaccine | “GVGH 1790GAHB Vaccine Against Shigella Sonnei” NCT02676895 ↗ |
| Route | Intramuscular | “by intramuscular injection” NCT03089879 ↗ |